Reneo Pharmaceuticals Management

Management Kriterienprüfungen 4/4

Reneo Pharmaceuticals' CEO ist Greg Flesher , ernannt in Nov 2020, hat eine Amtszeit von 3.58 Jahren. Die jährliche Gesamtvergütung beträgt $569.70K , bestehend aus 99% Gehalt und 1% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.069% der Aktien des Unternehmens, im Wert von $38.28K . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 3.1 Jahre bzw. 3.5 Jahre.

Wichtige Informationen

Greg Flesher

Geschäftsführender

US$569.7k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	99.0%
Amtszeit als Geschäftsführer	3.8yrs
Eigentum des Geschäftsführers	0.07%
Durchschnittliche Amtszeit des Managements	3.8yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

Recent updates

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Oct 03

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Apr 25

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Nov 22

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Aug 09

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Apr 22

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

Jan 20

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

Oct 02

Our First Look At Reneo Pharmaceuticals

Aug 15

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Greg Flesher im Vergleich zu den Einnahmen von Reneo Pharmaceuticals verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$57m
Mar 31 2024	n/a	n/a	-US$71m
Dec 31 2023	US$570k	US$564k	-US$77m
Sep 30 2023	n/a	n/a	-US$67m
Jun 30 2023	n/a	n/a	-US$61m
Mar 31 2023	n/a	n/a	-US$54m
Dec 31 2022	US$1m	US$545k	-US$52m
Sep 30 2022	n/a	n/a	-US$49m
Jun 30 2022	n/a	n/a	-US$49m
Mar 31 2022	n/a	n/a	-US$46m
Dec 31 2021	US$5m	US$475k	-US$40m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$28m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$529k	US$79k	-US$19m

Vergütung im Vergleich zum Markt: GregDie Gesamtvergütung ($USD569.70K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD673.68K).

Entschädigung vs. Einkommen: GregDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Greg Flesher (54 yo)

3.8yrs

Amtszeit

US$569,704

Vergütung

Mr. Gregory J. Flesher, also known as Greg, serves as President, Director and Chief Executive Officer of Reneo Pharmaceuticals, Inc since November 2020. He had been Consultant of Eledon Pharmaceuticals, In...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Grey	Founder & Executive Chairman	6.8yrs	US$215.13k	1.48% $ 757.0k
Gregory Flesher	President	3.8yrs	US$569.70k	0.069% $ 35.5k
Alejandro Dorenbaum	Chief Medical Officer	6.7yrs	US$466.23k	0% $ 0
Jennifer Lam	SVP of Finance & Administration and Principal Financial & Accounting Officer	no data	keine Daten	keine Daten
Michael Cruse	Chief Operating Officer	2.5yrs	US$781.47k	0.073% $ 37.4k

3.8yrs

Durchschnittliche Betriebszugehörigkeit

58.5yo

Durchschnittliches Alter

Erfahrenes Management: RPHMDas Führungsteam des Unternehmens gilt als erfahren (3.1 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Michael Grey	Founder & Executive Chairman	6.8yrs	US$215.13k	1.48% $ 757.0k
Gregory Flesher	President	3.8yrs	US$569.70k	0.069% $ 35.5k
Edward Mathers	Independent Director	6.8yrs	US$165.13k	0% $ 0
Niall O'Donnell	Director	6.8yrs	US$155.13k	0% $ 0
Stacey Seltzer	Independent Director	3.8yrs	US$166.63k	0% $ 0
Roshawn Blunt	Independent Director	2.1yrs	US$141.47k	0% $ 0
Balaji Muralidhar	Independent Director	3.8yrs	US$115.13k	0% $ 0
Paul Hoelscher	Independent Director	2.7yrs	US$175.13k	0% $ 0
Eric Dube	Independent Director	3.5yrs	US$170.63k	0% $ 0

3.8yrs

Durchschnittliche Betriebszugehörigkeit

51yo

Durchschnittliches Alter

Erfahrener Vorstand: RPHMDie Vorstandsmitglieder gelten als erfahren (3.5 Jahre durchschnittliche Amtszeit).

Reneo Pharmaceuticals Management

Management Kriterienprüfungen 4/4

Wichtige Informationen

Jüngste Management Updates

Chief Development Officer notifies of intention to sell stock

High number of new directors

Founder & Executive Chairman exercised options to buy US$165k worth of stock.

Reneo Pharmaceuticals, Inc. Appoints Roshawn Blunt to Its Board of Directors

High number of new directors

Dr. Lon Cardon Not Stands for Re-Election as Member of the Board of Reneo Pharmaceuticals, Inc

Recent updates

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell Small Cap Comp Value Index

OnKure, Inc. entered into an agreement to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM)

New major risk - Revenue and earnings growth

Concentra Biosciences, LLC submitted a non-binding proposal to acquire Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) for $60.8 million.

Price target decreased by 18% to US$20.98

Reneo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Reneo Pharmaceuticals, Inc. (NasdaqGM:RPHM) announces an Equity Buyback for 576,443 shares, for $4.4 million.

We're Not Very Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Chief Development Officer notifies of intention to sell stock

New minor risk - Profitability

Price target decreased by 9.1% to US$24.40

Reneo Pharmaceuticals, Inc. announced that it has received $5 million in funding from Abingworth LLP

Reneo Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from Abingworth LLP

Companies Like Reneo Pharmaceuticals (NASDAQ:RPHM) Are In A Position To Invest In Growth

Reneo Pharmaceuticals, Inc. Receives Fast Track Designation from the FDA for Mavodelpar (REN001) in a Genotype of Long-Chain Fatty Acid Oxidation Disorder (LC-FAOD)

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

High number of new directors

Price target increased to US$26.83

Founder & Executive Chairman exercised options to buy US$165k worth of stock.

We're Keeping An Eye On Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Rate

Reneo Pharmaceuticals, Inc. Appoints Roshawn Blunt to Its Board of Directors

Reneo Pharmaceuticals, Inc. Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study

Reneo Pharmaceuticals, Inc. to Present Data from Phase 1 REN001 Limb Immobilization Study at the 17th International Congress on Neuromuscular Diseases

Reneo Pharmaceuticals, Inc.(NasdaqGM:RPHM) dropped from Russell 2500 Value Index

Price target decreased to US$24.60

Price target decreased to US$30.00

High number of new directors

Dr. Lon Cardon Not Stands for Re-Election as Member of the Board of Reneo Pharmaceuticals, Inc

Is Reneo Pharmaceuticals (NASDAQ:RPHM) In A Good Position To Deliver On Growth Plans?

Reneo Pharmaceuticals, Inc. Announces Senior Leadership Promotions

Vineet R. Jindal to Resign as Reneo Pharmaceuticals, Inc.'s Chief Financial Officer, Effective March 31, 2022

We Think Reneo Pharmaceuticals (NASDAQ:RPHM) Can Afford To Drive Business Growth

High number of new directors

Here's Why We're Not Too Worried About Reneo Pharmaceuticals' (NASDAQ:RPHM) Cash Burn Situation

President recently bought US$64k worth of stock

Our First Look At Reneo Pharmaceuticals

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter